Study Group: Prescribers of Provigil (Modafinil) in the U.S.(?)
Council Members in this Study Group: 52
Request a survey with this Study Group
Leading Experts in this Study Group
Daniel Wynn, MD
Director, Clinical Research
Consultants In Neurology Ltd.
Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke, chronic...
Dean Traiger, MDPhysician
Physicians’ Primary Care of Southwest Florida,P.L.
Dean Traiger, MD, is the Owner of Physician's Primary Care of Southwest Florida. Dr. Traiger is board certified in Family Practice and specializes in general primary care across the continuum of pediatrics, adolescent, and adult and geriatric care. He is also focused on diabetes care, hypertension,...
President
Red Oak Psychiatry Associates, P. A.
Lawrence Ginsberg, MD, is President and CEO of Red Oak Psychiatry Associates, PA, a multidisciplinary mental health group in Houston, Texas. Dr. Ginsberg's research interests include psychopharmacology, addiction medicine, and forensic psychiatry. His areas of clinical expertise are attention deficit...
Louis Sanfilippo, MDPresident
LCS Group, LLC
Louis Sanfilippo, MD, is President of the LCS Group, since April 2008, a consulting firm focused on pharmaceutical development and market strategy. He is an Assistant Clinical Professor of Psychiatry at Yale School of Medicine and in private practice. Dr. Sanfilippo has served management and scientific...
Related Study Groups
| Study Group Name | Members |
|---|---|
| Physicians who Treat Insomnia (US) | 514 |
| Physicians who Treat ADHD (US) | 434 |
| Adderall XR Prescribers (US) | 84 |
| Lunesta Prescribers (US) | 272 |
| Ambien Prescribers (US) | 319 |
| Physicians who Treat Depression (US) | 381 |
| Psychiatrists (US) | 1116 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Abuse resistant long acting narcotics offer benefit as they are less desirable to those who might wish a quick high via snorting, injecting crushed time-release narcotic. Unfortunately, given the higher cost than long acting generics and increased pressure on physicians to prescribe generics, expect...
Astra Zeneca is pursuing important medical and, of course, commercial goals by seeking the expanded clinical indications of major depression and generalized anxiety disorder for Seroquel XR, heir to blockbuster Seroquel (quetiapine). This latest EU submission culminates regulatory submissions...
“Personalized medical diagnositics” looks to be evolving as a high impact area in neuropsychiatric drug development. Such ‘genetic biomarker’ platforms, based on either pharmacogenetic profiles coming from DNA blueprints or gene products from a simple blood draw, aim to identify patients who are...
‘One drug, many uses’ can make lots of sense clinically and commercially. Seeking additional FDA indications for a specific drug has obvious business benefits: greater revenue stream, improved branding, potentially longer market exclusivity, greater franchising potential of the drug...
Lundbeck has now disclosed the mechanism of action of its “mixed serotonin modulator and stimulator,” albeit buried in a first quarter report. Data on LuAA21004, Lundbeck’s lead antidepressant jointly in development with Takeda, was released at the Scandinavian College of Neuro-Psychopharmacology...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Other Freestanding Healthcare Facility
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Owner
- Physician - Director
- Director
- President
- Physician - Division Head
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms